Thrombin inhibitor
US-9217027-B2 · Dec 22, 2015 · US
US9827338B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9827338-B2 |
| Application number | US-201514657802-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 13, 2015 |
| Priority date | Jun 16, 2014 |
| Publication date | Nov 28, 2017 |
| Grant date | Nov 28, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided is a novel compound capable of being usefully used to diagnose and treat prostate cancer by labeling a radioisotope on a bombesin derivatives capable of selectively targeting a target material over-expressed in tumor cells in order to develop an effective diagnose and treatment method of diseases associated with prostate cancer.
Opening claim text (preview).
What is claimed is: 1. A bombesin derivatives represented by the following Chemical Formula 2: [In Chemical Formula 2, n is an integer of 1 to 3, m is an integer of 1 to 5, R 1 and R 2 are each independently hydrogen or [c1-c5]alkyl, X is a metal chelator and G is a glucose group or derivatives thereof,] and A: *-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH 2 . 2. The bombesin derivatives of claim 1 , wherein X includes one or more radioactive metal nuclides and is a metal chelator for a trivalent metal. 3. The bombesin derivatives of claim 2 , wherein the metal chelator for the trivalent metal is a DOTA-based chelator. 4. The bombesin derivatives of claim 2 , wherein the radioactive metal nuclide is for radiotherapy and is selected from the group consisting of 176 Yb, 111 In, 169 Gd, 177 Lu, 105 Rh, 111 Ag, 64 Cu, 67 Ga, 68 Ga, 125 I, 123 I, 129 I, and 166 Ho. 5. The bombesin derivatives of claim 1 , wherein in Chemical Formula 2, n is 3 and R 1 and R 2 are hydrogen. 6. The bombesin derivatives of claim 1 , wherein in G is R 3(s) are each independently hydrogen or a hydroxyl protecting group. 7. A preparation method of a bombesin derivatives comprising synthesizing a compound represented by the following Chemical Formula 2: [In Chemical Formula 2, n is an integer of 1 to 3, m is an integer of 1 to 5, X is a metal chelator, R 1 to R 2 are each independently hydrogen or (C1-C5)alkyl, A is *-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2, and G is a glucose group or derivatives thereof[. 8. A composition for diagnosis and treatment of diseases associated with the prostate comprising the bombesin derivatives of claim 1 .
the complex-forming compound being cyclic, e.g. DOTA · CPC title
Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins} · CPC title
Peptides; Proteins · CPC title
Gastrin releasing peptide (bombesin C07K7/086) · CPC title
having 5 to 11 amino acids · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.